Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression.

Molecular psychiatry·2026
Same author

Assessing the de novo paradigm in sporadic early-onset Alzheimer disease trios.

Molecular psychiatry·2026
Same author

Intracranial and Peripheral Inflammatory Biomarkers Predict Futile Recanalization After Endovascular Treatment.

Stroke·2026
Same author

Influence of Decreased Kidney Function on Plasma Biomarkers of Neurodegenerative Disorders in Routine Care: Confirmation of the Interest of Ratios.

Neurology·2026
Same author

Domain-adapted language model using reinforcement learning for various dementias.

medRxiv : the preprint server for health sciences·2026
Same author

Automated MRI-based atrophy patterns to improve the diagnosis of generalized epilepsies in outpatient care.

Seizure·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Germain Busto1, Cédric Turpinat2, Sophie Navucet3

  • 1CHU Montpellier CMRR, Montpellier, France.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Amyloid positivity alone does not predict Alzheimer's disease progression. Identifying specific biomarkers is crucial for predicting cognitive decline and guiding personalized treatment decisions for patients.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarkers
  • Alzheimer's Disease Research

Background:

  • Recent Alzheimer's disease (AD) advancements include disease-modifying treatments and blood-based biomarkers.
  • However, the predictive value of amyloid positivity alone for cognitive decline remains debated.
  • This highlights the need for better predictors to guide patient-centered clinical decisions.

Purpose of the Study:

  • To longitudinally monitor cognitively unimpaired, amyloid-positive individuals.
  • To identify biological parameters that predict cognitive decline.
  • To enable early intervention with disease-modifying treatments when appropriate.

Main Methods:

  • Recruitment of individuals from French memory clinics based on cognitive complaints or family history.
  • Baseline evaluations including neuropsychological tests, MRI, gut microbiota, proteomics (Nulisa), and sleep assessment.
  • Longitudinal monitoring using digital tools for remote detection of cognitive decline.

Main Results:

  • Establishment of a cohort of amyloid-positive patients screened via advanced plasma biomarkers (Aβ42, p-tau217).
  • Longitudinal evaluation to identify early cognitive decline.
  • Identification of predictive biological parameters for cognitive decline.

Conclusions:

  • Amyloid positivity alone is insufficient to initiate disease-modifying treatments due to variable progression and side effects.
  • The study aims to uncover key biological predictors of cognitive decline in amyloid-positive individuals.
  • Findings will support more informed, patient-centered clinical decisions in Alzheimer's disease management.